1. Introduction {#sec1-medicines-07-00032}
===============

Among all heat-related illness, heatstroke is the most severe spectrum of diseases defined by a condition in which the core body temperature exceeds 40 °C following a tremendous environmental heat load that overrides the body's heat dissipation efforts \[[@B1-medicines-07-00032]\]; it is accompanied by clinical central nervous system dysfunction and/or other organ failures \[[@B2-medicines-07-00032]\]. Heatstroke can be categorized based on its cause as either classic or exertional heatstroke \[[@B1-medicines-07-00032],[@B3-medicines-07-00032]\]. Classic heatstroke is commonly found among the elderly whose thermoregulation mechanism is compromised. It is caused by an imbalance between the absorption of environmental heat and heat dissipation. By contrast, exertional heatstroke generally occurs among healthy young people who have engaged in strenuous physical activity during periods of high temperature and humidity \[[@B4-medicines-07-00032],[@B5-medicines-07-00032]\]. This heavy activity causes excessive heat production, which overwhelms the heat-loss mechanism \[[@B6-medicines-07-00032]\].

Approximately, heatstroke in the United States (U.S.) results in 4100 emergency department visits per year, with most occurring during the summer and requiring hospitalization \[[@B7-medicines-07-00032]\]. The mortality rate ranges between 3--7% and is expected to rise in coming years due to climate change \[[@B8-medicines-07-00032],[@B9-medicines-07-00032],[@B10-medicines-07-00032]\]. One of the fatal complications of heatstroke is circulatory failure resulting from prolonged hyperthermia, which leads to physiological alterations and the dysregulation of inflammatory reactions. Several mechanisms have been proposed as the pathogenesis of circulatory failure in heatstroke, including hypovolemia, cardiac dysfunction, maldistribution of blood volume, and peripheral vascular failure \[[@B11-medicines-07-00032]\]. In addition, circulatory failure was previously reported as a prognostic factor \[[@B9-medicines-07-00032],[@B10-medicines-07-00032],[@B12-medicines-07-00032],[@B13-medicines-07-00032]\]. Therefore, the early identification of patients with risk factors for circulatory failure, and prompt treatment among them, might result in better outcomes. However, knowledge of the risk factors and the impact of circulatory failure among patients with heatstroke remains limited.

This study aimed to assess the risk factors and the association of circulatory failure with treatments, complications, outcomes, and resource use in patients hospitalized for heatstroke in the U.S.

2. Materials and Methods {#sec2-medicines-07-00032}
========================

2.1. Data Source {#sec2dot1-medicines-07-00032}
----------------

This cohort study was conducted using the 2003--2014 National Inpatient Sample (NIS) database. The NIS is the largest all-payer inpatient database in the United States. A discharge data set from a 20% stratified sample of hospitals in United States with the patient encounter-level information, which includes principal and secondary diagnosis codes as well as procedure codes, are recorded in the NIS. Sample weight is used to generate national estimates for hospitalization nationwide. The approval from an institutional review board was exempted as the information was obtained from a de-identified public database.

2.2. Study Population {#sec2dot2-medicines-07-00032}
---------------------

All patients who were admitted in hospitals from 2003 to 2014 with a principal diagnosis of heatstroke, based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) diagnosis code of 992.0, were included. Heatstroke patients were categorized based on the presence of circulatory failure during hospitalization. Circulatory failure, which was defined as any type of shock or hypotension, was identified using ICD-9 diagnosis of 785.5 (shock without mention of trauma), 785.50 (shock, unspecified), 785.59 (other shock without trauma, including hypovolemic shock), 785.51 (cardiogenic shock), 785.52 (septic shock), 458.8 (other specified hypotension), 458.9 (hypotension, unspecified), and 796.3 (nonspecific low blood pressure reading).

2.3. Data Collection {#sec2dot3-medicines-07-00032}
--------------------

Patient characteristics, treatments, complications, and outcomes during hospitalization were identified using ICD-9 codes, as previously described (\[[@B14-medicines-07-00032]\], Table S1). Patient characteristics included age, sex, race, smoking, alcohol drinking, obesity, diabetes mellitus, hypertension, hypothyroidism, chronic kidney disease, coronary artery disease, congestive heart failure, and atrial flutter/fibrillation. Treatments included invasive mechanical ventilation, blood component transfusion, and renal replacement therapy. Complications and outcomes included electrolyte derangements (hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, metabolic acidosis, metabolic alkalosis), rhabdomyolysis, sepsis, gastrointestinal bleeding, ventricular arrhythmia or cardiac arrest, end-organ failure (renal failure, respiratory failure, liver failure, neurological failure, hematological failure), and in-hospital mortality. Resource utilization included length of hospital stay and hospitalization cost.

2.4. Statistical Analysis {#sec2dot4-medicines-07-00032}
-------------------------

The total number of heatstroke patients was estimated using discharge-level weights provided by the Healthcare Cost and Utilization Project (HCUP). Continuous variables were reported as mean ± standard deviation and were compared using Student's *t*-test. Categorical variables were reported as counts with percentage and were compared using Chi-squared test. Multivariable logistic regression with forward stepwise selection was performed to assess if there were clinical characteristics independently associated with circulatory failure. The association of circulatory failure with treatments, complications, and outcomes was assessed using logistic regression analysis, and with length of hospital stay and hospitalization cost using linear regression analysis, with pre-specified adjustment for age, sex, smoking, alcohol drinking, and comorbidities. A two-tailed *p*-value of less than 0.05 was considered statistically significant. All analyses were two-tailed. Statistical significance was achieved when *p*-value \< 0.05. SPSS statistical software (version 22.0, IBM Corporation, Armonk, NY, USA) was used for all analyses.

3. Results {#sec3-medicines-07-00032}
==========

3.1. Incidence of and Risk Factors for Circulatory Failure in Hospitalized Heatstroke Patients {#sec3dot1-medicines-07-00032}
----------------------------------------------------------------------------------------------

A total of 3372 hospitalized heatstroke patients were included in analysis. Of these, 393 (12%) developed circulatory failure in hospital. [Table 1](#medicines-07-00032-t001){ref-type="table"} compares clinical characteristics, in-hospital treatments, complications, outcomes, and resource utilization between patients with and without circulatory failure. In multivariable analysis ([Table 2](#medicines-07-00032-t002){ref-type="table"}), obesity was independently associated with increased odds of circulatory failure, while age ≥ 60 was associated with decreased odds of circulatory failure.

3.2. The Association of Circulatory Failure with In-Hospital Treatments, Complication, and Outcomes {#sec3dot2-medicines-07-00032}
---------------------------------------------------------------------------------------------------

In terms of in-hospital treatments, patients with circulatory failure had higher odds of receiving invasive mechanical ventilation (OR 3.96; *p \<* 0.001), blood component transfusion (OR 4.60; *p \<* 0.001), and renal replacement therapy (OR 3.70; *p \<* 0.001) than patients without circulatory failure. In terms of in-hospital complications and outcomes, circulatory failure was significantly associated with hyperkalemia (OR 2.66; *p \<* 0.001), hypocalcemia (OR 2.77; *p \<* 0.001), metabolic acidosis (OR 2.90; *p \<* 0.001), metabolic alkalosis (OR 3.75; *p* = 0.001), sepsis (OR 3.93; *p \<* 0.001), gastrointestinal bleeding (OR 3.43; *p* = 0.006), ventricular arrhythmia/cardiac arrest (OR 4.45; *p \<* 0.001), renal failure (OR 2.03; *p \<* 0.001), respiratory failure (OR 3.64; *p \<* 0.001), liver failure (OR 3.27; *p \<* 0.001), neurological failure (OR 1.91; *p \<* 0.001), and hematological failure (OR 2.70; *p \<* 0.001). Patients with circulatory failure had 7.1-times higher odds of in-hospital mortality than patients without circulatory failure (*p* \< 0.001).

3.3. Impact of Circulatory Failure on Resource Utilization {#sec3dot3-medicines-07-00032}
----------------------------------------------------------

Compared with patients without circulatory failure, the mean length of hospital stay increased by 2.2 days (*p \<* 0.001), and the mean hospitalization cost increased by \$33,102 (*p \<* 0.001) in patients with circulatory failure ([Table 3](#medicines-07-00032-t003){ref-type="table"}).

4. Discussion {#sec4-medicines-07-00032}
=============

This is the largest cohort study demonstrating the impact of circulatory failure among heatstroke patients in the US. We found that 12% of hospitalized heatstroke patients had circulatory failure. The in-hospital mortality rate among hospitalized heatstroke patients with circulatory failure was 19.1%. In addition, heatstroke patients with circulatory failure were at great risk for complications, including metabolic ventricular arrhythmia, cardiac arrest, sepsis, gastrointestinal hemorrhage, metabolic abnormalities, and other end-organ failures. Further, patients had a higher risk of invasive mechanical ventilation, blood component transfusion, and renal replacement therapy. Obesity was associated with higher odds of circulatory failure, while advanced age was associated with lower odds of circulatory failure.

Circulatory failure is common among heatstroke patients. Our study demonstrated that patients who experience circulatory failure have a 7-fold higher mortality rate than those who do not. Circulatory failure is a well-known and significant factor for predicting deaths among the critically ill \[[@B15-medicines-07-00032]\]. Several previous studies have confirmed the impact of circulatory failure on death rates among heatstroke patients \[[@B9-medicines-07-00032],[@B10-medicines-07-00032],[@B12-medicines-07-00032],[@B13-medicines-07-00032]\]. Furthermore, circulatory failure not only affects mortality rates, it also results in various consequent complications. The occurrence of circulatory failure might reflect an uncompensated state in severe cases. Circulatory failure can result in a reduction of tissue perfusion and oxygen delivery, causing a variety of complications. The disproportion between metabolic demand and oxygen delivery during systemic inflammatory response in severe heatstroke may lead to type IV respiratory failure requiring mechanical ventilation \[[@B16-medicines-07-00032]\]. In addition, hypovolemia coexisting with myocardial dysfunction in severe cases may enhance the deterioration of renal blood flow, leading to acute kidney injury \[[@B17-medicines-07-00032],[@B18-medicines-07-00032]\].

In terms of the gastrointestinal tract, hemodynamic change, hypotension, and vasopressor use may reduce microcirculation flow of the gastrointestinal tract. During circulatory failure, there is systemic vasoconstriction of the arteriolar resistance vessels throughout the body, especially mesenteric vasoconstriction, to increase the circulating blood volume into the systemic circulation \[[@B19-medicines-07-00032]\]. In addition to activation of the sympathetic nervous system, the angiotensin II receptors of the mesenteric vascular resistance smooth muscle have a 5-fold affinity for angiotensin II. Thus gastrointestinal perfusion is often compromised early relative to other vascular beds during circulatory failure \[[@B20-medicines-07-00032]\]. The hypoperfusion along the gastrointestinal tract can lead to the dysfunction of several protective mechanisms causing stress-related mucosal ulcers and gastrointestinal hemorrhage \[[@B21-medicines-07-00032]\]. In addition, an increase of catecholamine tone during cardiovascular collapse, combined with extensive muscle injury-induced electrolyte abnormalities, might also enhance ventricular arrhythmia and cardiac arrest \[[@B22-medicines-07-00032],[@B23-medicines-07-00032]\]. These complications result in longer hospital stays and require more invasive treatments, which may, in turn, increase the risk of hospital-acquired infection and sepsis. Finally, complications from circulatory failure, such as multiorgan failures, electrolyte abnormalities, and cardiac arrhythmia, may also result in cardiac dysfunction. This vicious cycle cannot be explicitly concluded as the cause and effect of these complications with circulatory failure.

In this study, we demonstrated that obesity was associated with higher odds of circulatory failure. Obese patients tend to have higher heat production accompanied by insulator characteristics of adipose tissue. Higher sweat rates may be required to help dissipate the excess heat, as in previous reports \[[@B24-medicines-07-00032]\]. These higher sweat rates lead to water and salt loss. This loss, combined with systemic inflammatory response syndrome from prolonged hyperthermia, results in cardiovascular collapse and circulatory failure \[[@B25-medicines-07-00032],[@B26-medicines-07-00032]\]. Circulatory failure in heatstroke may be induced by several mechanisms, including hypovolemia caused by severe dehydration, heat stress-induced myocardial dysfunction, and the pooling of blood volume at the periphery \[[@B11-medicines-07-00032]\]. In addition to common mechanisms, exertional heatstroke seems to have a higher risk of hemodynamic compromise due to right ventricular dysfunction, which was not found in non-exertional heatstroke \[[@B18-medicines-07-00032],[@B27-medicines-07-00032]\]. An animal study demonstrated metabolic dysfunction in the myocardium following exertional heatstroke \[[@B28-medicines-07-00032]\]. These mechanisms might explain why younger patients who tend to suffer from exertional heatstroke are at higher risk of developing circulatory failure, while elderly heatstroke patients may be susceptible to non-exertional heatstroke, which is less likely to develop circulatory failure than exertional heatstroke.

This study has some limitations. First, the study may not detect patients whose condition is complicated with circulatory failure at the scene, since the NIS database is hospital-based. We may underestimate the impact of circulatory failure if patients are not admitted, or if they fully recover from cardiovascular collapse before admission. Moreover, we could not demonstrate information prior to hospital admission, such as the onset of heatstroke, and the long-term sequelae of circulatory failure among heatstroke patients. Given the structure of the NIS database, we could only show short-term complications and outcomes during their hospital stays. Finally, the study could not demonstrate differences in outcomes regarding the type of heatstroke.

5. Conclusions {#sec5-medicines-07-00032}
==============

In conclusion, approximately one out of nine heatstroke patients developed circulatory failure during hospitalization. Circulatory failure is associated with various complications, higher mortality rates, and increased resource use. Early detection, prompt treatment, and close monitoring of these complications might lower mortality and decrease resource use.
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###### 

Clinical characteristics, in-hospital treatments, complications, outcomes, and resource utilization in heatstroke patients.

                                          Total             Circulatory Failure   No Circulatory Failure   *p*-Value
  --------------------------------------- ----------------- --------------------- ------------------------ -----------
  Clinical characteristics                                                                                 
  N (%)                                   3372              393 (11.7)            2979 (88.3)              
  Age (years)                             55 ± 22           51 ± 22               55 ± 22                  \<0.001
  \<20                                    218 (6.5)         38 (9.7)              180 (6.0)                
  20--39                                  654 (19.4)        68 (17.3)             586 (19.7)               
  40--59                                  1034 (30.7)       147 (37.4)            887 (29.8)               
  60--79                                  900 (26.7)        93 (23.7)             807 (27.1)               
  ≥80                                     564 (16.7)        47 (12.0)             517 (17.4)               
  Male                                    2478 (73.6)       94 (23.9)             795 (26.7)               0.23
  Race                                                                                                     0.04
  Caucasian                               1883 (55.8)       218 (55.5)            1665 (55.9)              
  African American                        496 (14.7)        53 (13.5)             443 (14.9)               
  Hispanic                                428 (12.7)        66 (16.8)             362 (12.2)               
  Other                                   565 (16.8)        56 (14.2)             509 (17.1)               
  Smoking                                 604 (17.9)        58 (14.8)             546 (18.3)               0.08
  Alcohol drinking                        270 (8.0)         38 (9.7)              232 (7.8)                0.20
  Obesity                                 233 (6.9)         44 (11.2)             189 (6.3)                \<0.001
  Diabetes Mellitus                       562 (16.7)        57 (14.5)             505 (17.0)               0.22
  Hypertension                            1255 (37.2)       131 (33.3)            1124 (37.7)              0.09
  Hypothyroidism                          196 (5.8)         25 (6.4)              171 (5.7)                0.62
  Chronic kidney disease                  201 (6.0)         28 (7.1)              173 (5.8)                0.30
  Coronary artery disease                 389 (11.5)        40 (10.2)             349 (11.7)               0.37
  Congestive heart failure                216 (6.4)         24 (6.1)              192 (6.4)                0.80
  Atrial flutter/fibrillation             251 (7.4)         30 (7.6)              221 (7.4)                0.88
  Treatment                                                                                                
  Invasive mechanical ventilation         686 (20.3)        178 (45.3)            508 (17.1)               \<0.001
  Blood component transfusion             169 (5.0)         62 (15.8)             107 (3.6)                \<0.001
  Renal replacement therapy               75 (2.2)          26 (6.6)              49 (1.6)                 \<0.001
  Complication and outcomes                                                                                
  Hyponatremia                            293 (8.7)         41 (10.4)             252 (8.5)                0.19
  Hypernatremia                           183 (5.4)         25 (6.4)              158 (5.3)                0.38
  Hypokalemia                             500 (14.8)        47 (12.0)             453 (15.2)               0.09
  Hyperkalemia                            134 (4.0)         34 (8.7)              100 (3.4)                \<0.001
  Hypocalcemia                            73 (2.2)          19 (4.8)              54 (1.8)                 \<0.001
  Hypercalcemia                           37 (1.1)          6 (1.5)               31 (1.0)                 0.39
  Metabolic acidosis                      472 (14.0)        116 (29.5)            356 (12.0)               \<0.001
  Metabolic alkalosis                     29 (0.9)          10 (2.5)              19 (0.6)                 \<0.001
  Rhabdomyolysis                          1049 (31.1)       143 (36.4)            906 (30.4)               0.02
  Gastrointestinal bleeding               54 (1.6)          21 (5.3)              33 (1.1)                 \<0.001
  Sepsis                                  149 (4.4)         49 (12.5)             100 (3.4)                \<0.001
  Ventricular arrhythmia/cardiac arrest   95 (2.8)          33 (8.4)              62 (2.1)                 \<0.001
  Renal failure                           1226 (36.4)       203 (51.7)            1023 (34.3)              \<0.001
  Respiratory failure                     550 (16.3)        147 (37.4)            403 (13.5)               \<0.001
  Liver failure                           196 (5.8)         58 (14.8)             138 (4.6)                \<0.001
  Neurological failure                    651 (19.3)        118 (30.0)            533 (17.9)               \<0.001
  Hematological failure                   449 (13.3)        108 (27.5)            341 (11.4)               \<0.001
  In-hospital mortality                   168 (5.0)         75 (19.1)             93 (3.1)                 \<0.001
  Resource utilization                                                                                     
  Length of hospital stay (days)          4.3 ± 7.0         6.4 ± 10.6            4.0 ± 6.3                \<0.001
  Hospitalization cost (\$)               35,335 ± 72,085   66,999 ± 120,863      31,140 ± 61,671          \<0.001

Continuous variables are reported as mean ± standard deviation, categorical variables as counts (percentages).
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###### 

Univariable and multivariable analysis assessing factors associated with circulatory failure in heatstroke patients.

  Variables                     Univariable Analysis   Multivariable Analysis                       
  ----------------------------- ---------------------- ------------------------ ------------------- -------
  Age (years)                                                                                       
  \<20                          1.27 (0.86--1.88)      0.23                     1.32 (0.89--1.95)   0.16
  20--39                        0.70 (0.52--0.95)      0.02                     0.72 (0.53--0.97)   0.03
  40--59                        1 (reference)                                   1 (reference)       
  60--79                        0.70 (0.53--0.92)      0.01                     0.71 (0.54--0.94)   0.02
  ≥80                           0.55 (0.39--0.78)      0.001                    0.58 (0.41--0.81)   0.002
  Male                          1.16 (0.91--1.48)      0.24                                         
  Race                                                                                              
  Caucasian                     1 (reference)                                                       
  African American              0.91 (0.67--1.26)      0.58                                         
  Hispanic                      1.39 (1.03--1.88)      0.03                                         
  Other                         0.84 (0.62--1.15)      0.27                                         
  Smoking                       0.77 (0.58--1.04)      0.08                                         
  Alcohol drinking              1.27 (0.88--1.82)      0.20                                         
  Obesity                       1.86 (1.32--2.63)      \<0.001                  1.76 (1.24--2.50)   0.002
  Diabetes Mellitus             0.83 (0.62--1.12)      0.22                                         
  Hypertension                  0.83 (0.66--1.03)      0.09                                         
  Hypothyroidism                1.12 (0.72--1.72)      0.62                                         
  Chronic kidney disease        1.24 (0.82--1.88)      0.30                                         
  Coronary artery disease       0.42 (0.21--0.83)      0.01                                         
  Congestive heart failure      0.82 (0.41--1.62)      0.57                                         
  Atrial flutter/fibrillation   1.04 (0.58--1.87)      0.89                                         
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###### 

The association of circulatory failure with in-hospital treatment, complications, outcomes, and resource utilization in heatstroke patients.

                                          Univariable Analysis      Multivariable Analysis                                   
  --------------------------------------- ------------------------- ------------------------ ------------------------------- -----------
  Treatments                                                                                                                 
  Invasive mechanical ventilation         4.03 (3.23--5.02)         \<0.001                  3.96 (3.11--5.03)               \<0.001
  Blood component transfusion             5.03 (3.60--7.01)         \<0.001                  4.60 (3.25--6.53)               \<0.001
  Renal replacement therapy               4.24 (2.60--6.90)         \<0.001                  3.70 (2.15--6.35)               \<0.001
  Complications and outcomes                                                                                                 
  Hyponatremia                            1.26 (0.89--1.79)         0.19                     1.28 (0.89--1.82)               0.18
  Hypernatremia                           1.21 (0.79--1.88)         0.39                     1.19 (0.76--1.86)               0.44
  Hypokalemia                             0.76 (0.55--1.04)         0.09                     0.79 (0.57--1.09)               0.14
  Hyperkalemia                            2.73 (1.82--4.09)         \<0.001                  2.66 (1.76--4.04)               \<0.001
  Hypocalcemia                            2.75 (1.61--4.69)         \<0.001                  2.77 (1.60--4.79)               \<0.001
  Hypercalcemia                           1.47 (0.61--3.56)         0.39                     1.55 (0.62--3.86)               0.35
  Metabolic acidosis                      3.09 (2.42--3.94)         \<0.001                  2.90 (2.25--3.73)               \<0.001
  Metabolic alkalosis                     4.07 (1.88--8.81)         \<0.001                  3.75 (1.68--8.40)               0.001
  Rhabdomyolysis                          1.31 (1.05--1.63)         0.02                     1.25 (0.99--1.58)               0.06
  Sepsis                                  4.10 (2.86--5.88)         \<0.001                  3.93 (2.70--5.73)               \<0.001
  Gastrointestinal bleeding               5.04 (2.89--8.80)         \<0.001                  3.43 (1.42--8.25)               0.006
  Ventricular arrhythmia/cardiac arrest   4.31 (2.79--6.67)         \<0.001                  4.45 (2.83--7.00)               \<0.001
  Renal failure                           2.04 (1.65--2.53)         \<0.001                  2.03 (1.62--2.54)               \<0.001
  Respiratory failure                     3.82 (3.04--4.81)         \<0.001                  3.64 (2.86--4.64)               \<0.001
  Liver failure                           3.56 (2.57--4.94)         \<0.001                  3.27 (2.30--4.65)               \<0.001
  Neurological failure                    1.97 (1.56--2.49)         \<0.001                  1.91 (1.50--2.42)               \<0.001
  Hematological failure                   2.93 (2.29--3.76)         \<0.001                  2.70 (2.07--3.52)               \<0.001
  In-hospital mortality                   7.30 (5.28--10.11)        \<0.001                  7.09 (5.04--9.96)               \<0.001
                                          Coefficient (95% CI)      *p*-value                Adjusted coefficient (95% CI)   *p*-value
  Resource utilization                                                                                                       
  Length of hospital stay (days)          2.4 (1.6--3.1)            \<0.001                  2.2 (1.4--2.9)                  \<0.001
  Hospitalization cost (\$)               35,859 (28,330--43,388)   \<0.001                  33,102 (25,596--40,609)         \<0.001

\* Adjusted for age, sex, race, smoking, alcohol drinking, obesity, diabetes mellitus, hypertension, hypothyroidism, and chronic kidney disease, chronic ischemic heart disease, congestive heart failure, and atrial flutter/fibrillation.
